|Bid||298.13 x 1100|
|Ask||298.69 x 1200|
|Day's Range||297.08 - 299.70|
|52 Week Range||287.66 - 442.00|
|Beta (3Y Monthly)||0.99|
|PE Ratio (TTM)||14.16|
|Earnings Date||Aug 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||391.16|
Regeneron Pharmaceuticals Inc., Ryanair Holdings PLC, Iron Mountain Inc. and Molson Coors Brewing Co. have declined to their respective three-year lows Continue reading...
In early May, President Donald Trump announced that he would be requiring Big Pharma to list the prices of their drugs in their TV advertisements.
The FDA accepts for review Sanofi's (SNY) BLA for isatuximab as a potential treatment for relapsed/refractory multiple myeloma. The FDA will declare its decision by April 2020.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
TARRYTOWN, N.Y. , July 8, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2019 financial and operating results on Tuesday, August ...
Glaxo (GSK) gets an EU approval for Dovato, its single-tablet two-drug HIV regimen. It commences phase III studies on its anti GM-CSF antibody, otilimab, for patients with rheumatoid arthritis.
Pfizer's (PFE) Eucrisa ointment is found safe in a late-stage label expansion study for treating mild to moderate atopic dermatitis in minors aged 3 months to 2 years.
Regeneron's (REGN) Dupixent gets favorable recommendation from CHMP for moderate-to-severe atopic dermatitis in adolescents aged 12-17 years.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has granted conditional marketing authorization for Libtayo® (cemiplimab) for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation. "With no other medical treatments approved for advanced CSCC in the EU, Libtayo represents an important new option for patients affected with this advanced skin cancer who cannot be cured by surgery or radiation," said Axel Hauschild, M.D., Ph.D., an investigator in the pivotal CSCC clinical program and Professor and Head of the Interdisciplinary Skin Cancer Center at the University Hospital Schleswig-Holstein in Kiel, Germany.
It can be tough to pick winners in the world of pharmaceutical development, but Alexion, Regeneron, and Ionis offer investors good chances of strong returns.
Regeneron (REGN) and partner Sanofi obtain FDA approval for Dupixent for the treatment of chronic rhinosinusitis with nasal polyposis in adults.
The U.S. Food and Drug Administration on Wednesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug Dupixent to treat nasal polyps, marking the third major use for the injectable medicine. The expanded label, which could significantly boost annual sales, is for use with other medicines to treat patients suffering from chronic rhinosinusitis with nasal polyps, the companies said in a joint statement. The FDA first approved Dupixent in 2017 for moderate-to-severe atopic dermatitis, or eczema, and in 2018 it won U.S. approval to treat moderate-to-severe asthma as well.
PARIS and TARRYTOWN, N.Y., June 26, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for use with other medicines to treat chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not controlled. CRSwNP can be a debilitating condition, with many patients opting for systemic steroids or nasal surgery which often cannot control this disease.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for use with other medicines to treat chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not controlled. CRSwNP can be a debilitating condition, with many patients opting for systemic steroids or nasal surgery, which often cannot control this disease.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 25) ArQule, Inc. (NASDAQ: ARQL ) Zai Lab Ltd (NASDAQ: ZLAB ...
Ocular (OCUL) clinches the FDA approval for the label expansion of Dextenza to treat ocular inflammation following ophthalmic surgery.
Health-care reform is coming, UBS analysts say, and it could have severe consequences for health companies.
AnaptysBio stock tumbled Friday after the results of a study from Regeneron Pharmaceuticals and Sanofi cast doubt on the biotech company's ability to compete in asthma treatment.